Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?
11
77
Ṁ377Ṁ361
2025
82%
chance
1D
1W
1M
ALL
The rise of GPL-1 agonists as "miracle" drugs to cure obesity, hypertension, and a myriad of social issues related to an unhealthy body mass has been nothing short of stunning -- as important as the development of AI. But we are just learning about the other potential effects of these. Will a new clinical trial at least confirm what we think we know about this class of drugs?
Get Ṁ200 play money
Related questions
Will there be medical consensus that GLP-1 drugs have cardiovascular benefits beyond those provided via weight loss?
66% chance
Will any NLRP3 inhibitor drug be approved in 2023?
48% chance
Will 10 million Americans be on semaglutide (or yet-to-be-approved equally good or superior alternatives) by the end of 2030?
73% chance
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
31% chance
Will Medicare or Medicaid cover weight loss drugs by 2029?
76% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
73% chance
Will Jose Luis Ricon try semaglutide/tirzepatide in 2024?
20% chance